Among the many innovative new medicines launched in 2023, one approval stands out in terms of innovation – Vertex and CRISPR Therapeutics’ sickle cell and beta thalassemia gene therapy Casgevy, the first CRISPR-edited gene therapy to reach the market.
The story of how Casgevy (exagamglogene autotemcel, exa-cel) was developed is a remarkable one, not least because of the exceptional...